TL;DR - Q2 2026 adjusted EPS $0.77 — beat the $0.68 consensus by $0.09 (+13.2%) - Total revenue $15.0B, above analyst estimates; growth driven by non-COVID portfolio - Eliquis +19%, Padcev +23%, Lorbrena +37%, Vyndaqel +8% operationally - Paxlovid (COVID-19 antiviral) -95%; full-year COVID revenue guidance cut to ~$4B - FY2026 revenue guidance raised to $60.5–$62.5B (from $59.5–$62.5B) - GAAP net loss $248M, $(0.04)/share as reported — includes charges from Seagen-related write-downs
Q2 2026 Results
Summary
| Metric | Q2 2026 | vs. Estimate |
|---|---|---|
| Total Revenue | $15.0B | Topped ~$14.4B consensus |
| Adjusted EPS | $0.77 | Beat $0.68 est. (+$0.09) |
| GAAP EPS | $(0.04) | GAAP net loss $248M |
Pfizer beat Wall Street on both revenue and adjusted earnings in the second quarter of 2026. Total revenues of $15.0 billion exceeded the analyst consensus estimate of approximately $14.4 billion. Adjusted diluted EPS of $0.77 beat the $0.68 consensus by 13.2%.
On a GAAP basis, Pfizer reported a net loss of $248 million, or $(0.04) per share as stated in the official press release. This compares to a $2.91 billion GAAP profit in Q2 2025 and primarily reflects non-cash write-downs, including charges on experimental assets from the Seagen portfolio, according to media reports citing company filings.
Key Product Performance (Operational Growth)
| Product | Indication | Q2 2026 Operational |
|---|---|---|
| Lorbrena | ALK+ non-small cell lung cancer | +37% |
| Padcev | Urothelial carcinoma | +23% |
| Eliquis | Anticoagulation (blood clot prevention) | +19% |
| Vyndaqel family | ATTR cardiomyopathy | +8% |
| Comirnaty | COVID-19 vaccine | -34% |
| Paxlovid | COVID-19 antiviral | -95% |
Eliquis, co-promoted with Bristol Myers Squibb, is Pfizer's largest non-COVID revenue contributor by dollar volume. Padcev, acquired through Pfizer's $43 billion Seagen deal (2023), is co-commercialized with Astellas under a collaboration agreement in which Pfizer records net product revenue from U.S. sales and shares costs and profits 50/50 with Astellas. Lorbrena is a Pfizer-originated ALK inhibitor (FDA-approved November 2018, predating Seagen) whose growth reflects penetration in ALK-positive lung cancer.
Paxlovid's 95% operational decline reflects lower COVID-19 infection rates and a narrower prescribing recommendation. Comirnaty fell 34% on reduced vaccination demand.
Guidance and Investment Considerations
Full-Year 2026 Guidance Update
Pfizer raised the low end of its FY2026 revenue guidance by $1 billion:
| Previous | Updated | |
|---|---|---|
| Revenue range | $59.5–$62.5B | $60.5–$62.5B |
| COVID-19 products | ~$5B | ~$4B |
| Non-COVID products | (implied) | +$1.5B vs. prior forecast |
| Adjusted diluted EPS | $2.80–$3.00 | $2.80–$3.00 (reaffirmed) |
The net $500 million improvement at the guidance midpoint (now $61.5B) reflects non-COVID drug outperformance of $1.5 billion more than offsetting a $1 billion downward revision to COVID products.
Management also announced an additional $2.5 billion in cost efficiency savings targeted for 2027–2029, building on existing programs. CEO Albert Bourla stated: "Pfizer had another strong quarter, delivering on our financial commitments and advancing our strategy."
Investment Considerations
Non-COVID portfolio viability: The core thesis for Pfizer's recovery has been whether its post-pandemic drug portfolio can absorb the ongoing COVID unwind. Q2 2026 provides a positive data point: Eliquis, Padcev, Lorbrena, and Vyndaqel are all growing operationally, and non-COVID products are outperforming management's own forecasts by $1.5 billion.
Seagen write-down risk: Pfizer paid $43 billion for Seagen in 2023. The portfolio has already produced at least one substantial non-cash write-down on an experimental lung-cancer candidate, contributing to the Q2 2026 GAAP loss. Padcev, Seagen's primary commercial asset, is growing at 23% operationally — but investors will watch whether additional impairments emerge from the broader Seagen pipeline.
GAAP vs. adjusted divergence: The gap between a $(0.04) GAAP EPS and a $0.77 adjusted EPS is substantial. Investors focused on adjusted metrics should monitor which non-recurring charges persist into future quarters.
COVID floor watch: FY2026 COVID guidance is now ~$4 billion, approaching a trough. Any seasonal resurgence in infections could provide upside; further erosion is a known tail risk.
This article is for informational purposes only and does not constitute investment advice. LineVest News is not a registered investment advisor.
Sources - Pfizer Q2 2026 Earnings Release — BusinessWire - Yahoo Finance: Pfizer beats quarterly profit estimates on Eliquis - Yahoo Finance: Pfizer's Quarterly Results Beat Expectations on Cancer, Heart Drugs - CNBC: Pfizer tops estimates, hikes low end of revenue guidance - StreetInsider: PFE Tops Q2 EPS by 9c, Beats on Revenue
